April 2015

When Moving to Collaborative Care, a Challenge Is Figuring Out How to Pay for It

April 29, 2015

Evidence-Based Diabetes Management

Studies have shown that embedding behavioral health services into the primary care practice produces better health outcomes for patients with diabetes, while reducing indications of depression. The challenge is figuring out how to make the transition to new payment models that reward such care.

Studies Are Showing SGLT2s Also Help Control Hypertension, Eliminate Some Side Effects

May 04, 2015

Evidence-Based Diabetes Management

Real-world studies of SGLT2 inhibitors show that this new class of drugs for type 2 diabetes has lowered A1C more than rivals. Patients lose more weight than with other oral therapies, and the benefit of controlling hypertension may make it possible for some patients to stop taking other drugs.

What NCQA Recognition Means for Patients With Diabetes

May 05, 2015

Evidence-Based Diabetes Management

Joslin Diabetes Center has earned the highest level of recognition from the National Committee for Quality Assurance, which cited the center's strengths in communication, access, and coordination of care in the citation for a Patient-Centered Specialty Practice.

A Look at the Unhealthiness of Sitting, and a Call for More Research on Its Effects

May 05, 2015

Evidence-Based Diabetes Management

The meta-analysis in Annals of Internal Medicine found that small doses of exercise were not enough to offset the effects of long periods of sitting on all-cause mortality and chronic disease, including diabetes.

TV Watching Appears Worse Than Other Forms of Sitting

May 05, 2015

Evidence-Based Diabetes Management

Several recent studies have singled out too much TV watching as being associated with a higher risk of all cause mortality and a string of health problems, from diabetes and obesity to colorectal cancer.

Implementing JNC 8 Guidelines Is Generally Cost-Effective, According to NEJM Findings

May 05, 2015

Evidence-Based Diabetes Management

The argument for cost-effectiveness has become important in the care of patients with diabetes and other comorbidities, as patients typically take multiple medications, each with its own cost-both to the payer and to the patient in the form of a co-pay-as well as some side effects.

Higher-Dose Liraglutide Creates New Options to Fight Obesity, but Payment Remains a Challenge

May 05, 2015

Evidence-Based Diabetes Management

Saxenda was approved in December 2014 to treat obesity, giving physicians another option for patients who are overweight and battling diabetes. Experts say payers need to take obesity as seriously as other conditions when making decisions about covering therapies.